NIAID’s Radiation Nuclear Countermeasures Program (RNCP)
seeks support to assess current methodology and variations in radiation dosing
in in vivo and in vitro studies performed as
part of the development of medical countermeasures to address radiation
Through a new request for proposals, RNCP-Wide Dosimetry Guidance and Monitoring of Sources and
Irradiation Protocols (Clinical Trials Not Allowed), NIAID is soliciting an
offeror to assess the current state of radiation dosimetry within RNCP;
ultimately, RNCP will use the results to develop a consistent means of comparison
and reproducibility across institutes.
Under this effort, the contractor will:
- Establish an inventory of detailed information
on the irradiators used by institutions within the RNCP-funded portfolio.
- Conduct an initial evaluation on the status of
dosimetry methods and accuracy of radiation exposures delivered at institutions
across the RNCP-funded portfolio.
- Conduct baseline evaluations of each
RNCP-selected irradiator using the contractor’s existing phantom or dosimetry
methodology and determine institution variations.
- Work remotely with staff at RNCP-funded
institutions to determine if any modifications are needed to improve the
accuracy of radiation exposures.
- Conduct on-site evaluations whenever consistent
dose uniformity cannot be achieved remotely.
- Draft a standard operating procedure specific to
each participating institution to provide clear steps and guidelines on
reproducing accurate and consistent radiation exposures.
This contract will not support drug
development activities to identify medical countermeasures or developing pilot
biomarkers, biodosimetry devices, or performance of animal efficacy studies.
Consider submitting an offer if you can provide services,
facilities, expertise, and capabilities needed to develop a centralized dosimetry
harmonization effort. Ideally, you will have preliminary data demonstrating
consistent and accurate dosimetry exposures within a clearly defined radiation
exposure system that is used for nonclinical radiation animal (and in
vitro) studies in more than one animal species (e.g., mouse and nonhuman
NIAID will award one cost-reimbursement type
contract for one base year with as many as four additional one-year
The deadline for this opportunity is July 19, 2019, at 3 p.m. Eastern time. Contact Emily Bannister if you have any questions.
The effects of radiation on the body may appear within
minutes or develop many years after exposure. Radiation injury is directly
proportional to the dose absorbed by the body and radiosensitive tissues.
Depending on the dose of whole-body or partial-body exposure to external
radiation, the effects can range from an increased risk of cancer and tissue
fibrosis years after exposure to more acute effects, including transient nausea
and vomiting; hematopoietic and gastrointestinal injury, leading to immunosuppression
and infection; metabolic abnormalities; hemorrhage and anemia; damage to the
cardiovascular, pulmonary, and central nervous systems; and death.
The United States Government has recognized the need for
improved medical countermeasures against such threats. The Department of Health
and Human Services (HHS) charged the National Institute of Allergy and
Infectious Diseases (NIAID), Division of Allergy, Immunology and
Transplantation (DAIT) within the National Institutes of Health (NIH) with
building and managing a program to develop products for the mitigation or treatment
of radiation exposures resulting from nuclear and radiological attacks.
In 2012, the NIH published an update to its 2005 Strategic Plan and Research Agenda for Medical Countermeasures against Radiological and Nuclear Threats.
The original Strategic Plan and the update describes a multifaceted program promoting the development of medical countermeasures against radiological and nuclear threats. Since 2005, NIAID has sponsored early-stage research and product development programs and additional targeted initiatives focused on hematopoietic, gastrointestinal, pulmonary, cutaneous and combined injury and radionuclide decorporation.
The coordination between the NIH and other component
agencies of HHS to support the research and development of medical
countermeasures is outlined in the HHS
Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy
and Implementation Plan.